United Therapeutics (UTHR) EPS (Basic) (2009 - 2026)

United Therapeutics has disclosed EPS (Basic) across 18 years of filings, most recently posting $7.82 for Q2 2026.

• In Q2 2026, EPS (Basic) rose 13.91% year-over-year to $7.82; the TTM figure through Jun 2026 stood at $30.77 (up 11.73% YoY), while the FY2025 annual figure was $30.13, up 13.95% from the prior year.
• EPS (Basic) came in at $7.82 for Q2 2026 at United Therapeutics, up from $6.32 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $8.22 in Q4 2025 to a low of $2.56 in Q2 2022.
• Average EPS (Basic) over 5 years is $5.98, with a median of $6.29 recorded in 2024.
• The largest YoY upside for EPS (Basic) was 736.45% in 2022 against a maximum downside of 33.68% in 2022.
• Over 5 years, EPS (Basic) stood at $2.9 in 2022, then surged by 59.78% to $4.64 in 2023, then jumped by 43.7% to $6.67 in 2024, then increased by 23.37% to $8.22 in 2025, then retreated by 4.94% to $7.82 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $7.82 in Q2 2026, $6.32 in Q1 2026, and $8.22 in Q4 2025.